Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Reform Speeds Drug Development, At Least At The Signing Ceremony

This article was originally published in The Pink Sheet Daily

Executive Summary

President Obama announce seven initiatives to help move ideas from the lab to market as he signs the Leahy-Smith America Invents Act.

You may also be interested in...

We’re #8! PTO Ranks The Economic Power Of Pharma’s Patents

Pharmaceuticals falls below computers, communications and electrical equipment in “patent intensity” – the ratio of patents to jobs – according to a Patent and Trademark Office report on the importance of intellectual property to the U.S. economy.

Patent Owners Struck With “Sticker Shock” At PTO’s Proposed Fees

The Patent and Trademark Office issued a proposed fee schedule as part of its implementation of the Leahy-Smith America Invents Act; post-grant review fees could deter use of the procedure, Lilly’s general counsel says.

White House Credits Eli Lilly With Help In Final Deal On Patent Reform Bill

At President Obama's urging the CEOs of Lilly and Cisco met with Commerce Department officials to hammer out their differences to get the legislation through Congress.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts